Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|August 3, 2018

AuroMedics Pharma Issues Voluntary Recall Due to Glass and Silicone Particulates

AuroMedics Pharma issued a voluntary, nationwide recall of two lots of piperacillin and tazobactam for injection, USP 3.375 g due to the presence of particulates identified as glass and silicone material.

On July 31, 2018, AuroMedics Pharma issued a voluntary, nationwide recall of two lots of piperacillin and tazobactam for injection, USP 3.375 g due to the presence of particulates identified as glass and silicone material.

Each vial contains 7.05 mEq (162 mg) of sodium in a single-dose vial to the hospital level. One vial from lot PP0317012-A was found to contain particulate matter identified as glass within the vial, and another vial from lot PP0317059-A was found to contain silicone material. 

FDA reports that the presence of particulate matter was discovered as a result of two product complaints in which the contents of one vial from batch PP0317012-A was found to contain a glass particle and the contents of one vial from batch PP0317059A was found to contain a silicone particle.

According to FDA, administration of glass or silicone particulates may result in local irritation or swelling in response to the foreign material. More serious potential outcomes would include blockage and clotting in blood vessels. To date, the company has not received reports of any adverse events or identifiable safety concerns attributed to the product consumed from these lots, according to FDA.

Piperacillin and tazobactam for injection are used to treat moderate-to-severe infections caused by susceptible isolates of the designated bacteria in intra-abdominal, skin, skin-structure, and female pelvic infections, as well as community-acquired and nosocomial pneumonia. 

AuroMedics shipped the entire PP0317012-A lot to wholesalers and hospitals nationwide on June 30, 2017. Lot PP0317059-A was shipped November 27, 2017 through January 29, 2018.

FDA states that consumers, distributors, and retailers with the recalled product lots should stop all usage and return the product to its place of purchase or contact their doctor as appropriate.

Adverse reactions or quality problems associated with this product may be reported to FDA's MedWatch adverse event reporting program.

Source: FDA

Related to this article

View more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more